PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $868,550 | -29.7% | 83,756 | -2.9% | 0.00% | 0.0% |
| Q2 2023 | $1,235,744 | +81.9% | 86,295 | -9.3% | 0.00% | +50.0% |
| Q1 2023 | $679,492 | -38.1% | 95,167 | -2.7% | 0.00% | -50.0% |
| Q4 2022 | $1,097,080 | +14.2% | 97,779 | +12.8% | 0.00% | +33.3% |
| Q3 2022 | $961,000 | +29.7% | 86,688 | -1.3% | 0.00% | +50.0% |
| Q2 2022 | $741,000 | +22.9% | 87,840 | +98.3% | 0.00% | +100.0% |
| Q1 2022 | $603,000 | +105.8% | 44,300 | +197.3% | 0.00% | 0.0% |
| Q4 2021 | $293,000 | -38.7% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $478,000 | -5.2% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $504,000 | -10.0% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $560,000 | +13.1% | 14,900 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $495,000 | -19.1% | 14,900 | -10.8% | 0.00% | -50.0% |
| Q3 2020 | $612,000 | +11.3% | 16,700 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $550,000 | +27.6% | 16,700 | 0.0% | 0.00% | +100.0% |
| Q1 2020 | $431,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $77,669,000 | 45.24% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $218,878,000 | 17.56% |
| Abingworth LLP | 1,203,135 | $45,057,000 | 15.56% |
| Greenspring Associates, LLC | 360,939 | $13,557,000 | 10.78% |
| Penn Mutual Asset Management, LLC | 86,940 | $3,265,000 | 3.69% |
| RA Capital Management | 3,115,008 | $117,000,000 | 1.76% |
| Rhenman & Partners Asset Management AB | 175,000 | $6,573,000 | 0.46% |
| Summit Rock Advisors, LP | 34,100 | $1,281,000 | 0.44% |
| Eventide Asset Management | 600,000 | $22,536,000 | 0.33% |
| Parkman Healthcare Partners LLC | 30,207 | $1,135,000 | 0.26% |